Net clinical benefit of rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation: A subgroup analysis of J-ROCKET AF

Journal of Stroke and Cerebrovascular Diseases

Volumn 23, Issue 5, 2014, Pages 1142-1147

  Uchiyama, Shinichiro ^a   Hori, Masatsugu ^b   Matsumoto, Masayasu ^c   Tanahashi, Norio ^d   Momomura, Shin Ichi ^e   Goto, Shinya ^f   Izumi, Tohru ^g   Koretsune, Yukihiro ^h   Kajikawa, Mariko ⁱ   Kato, Masaharu ⁱ   Ueda, Hitoshi ⁱ   Iekushi, Kazuma ⁱ   Yamanaka, Satoshi ⁱ   Tajiri, Masahiro ⁱ  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f TOKAI UNIVERSITY   (Japan)

^g KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h OSAKA NATIONAL HOSPITAL   (Japan)

ⁱ BAYER YAKUHIN LTD   (Japan)

Author keywords

Atrial fibrillation; net clinical benefit; oral anticoagulation; stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; TREATMENT OUTCOME; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; ETHNOLOGY; JAPAN; MORTALITY; PROSPECTIVE STUDY; RISK FACTOR; STROKE; TIME;

ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; HUMANS; INTRACRANIAL HEMORRHAGES; JAPAN; MORPHOLINES; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 84901357226     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2013.10.001     Document Type: Article

References (22)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
2. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery A.J. Camm et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
3. D. Kubitza, M. Becka, and A. Roth et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects Curr Med Res Opin 24 2008 2757 2765
4. D. Kubitza, M. Becka, and G. Wensing et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 2005 873 880
5. E. Perzborn, J. Strassburger, and A. Wilmen et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor J Thromb Haemost 3 2005 514 521
6. B.F. Gage, A.D. Waterman, and W. Shannon et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation JAMA 285 2001 2864 2870
7. G.Y. Lip, R. Nieuwlaat, and R. Pisters et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation Chest 137 2010 263 272
8. M. Hori, M. Matsumoto, and N. Tanahashi et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study Circ J 76 2012 2104 2111
9. A.J. Camm, G.Y. Lip, and R. De Caterina et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 33 2012 2719 2747
10. A.C. Skanes, J.S. Healey, and J.A. Cairns et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control Canad J Cardiol 28 2012 125 136
11. R. Pisters, D.A. Lane, and R. Nieuwlaat et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
12. D.A. Garcia Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation Thromb Res 129 2012 9 16
13. D.E. Singer, Y. Chang, and M.C. Fang et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation Ann Int Med 151 2009 297 305
14. L. Friberg, M. Rosenqvist, and G.Y. Lip Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study Circulation 125 2012 2298 2307
15. Japanese guidelines for the management of stroke 2009 J Stroke Cerebrovasc Dis 20 2011 S197 S209
16. M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Eng J Med 365 2011 883 891
17. T. Tanigawa, M. Kaneko, and K. Hashizume et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation Drug metabol Pharm 28 2013 59 70
18. P.P. Glasziou, and L.M. Irwig An evidence based approach to individualising treatment BMJ 311 1995 1356 1359
19. M.C. Fang, A.S. Go, and Y. Chang et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages Am J Med 120 2007 700 705
20. E.M. Hylek, A.S. Go, and Y. Chang et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation N Engl J Med 349 2003 1019 1026
21. A. Banerjee, D.A. Lane, and C. Torp-Pedersen et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study Thromb Haemost 107 2012 584 589
22. J.B. Olesen, G.Y. Lip, and A.L. Kamper et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease N Engl J Med 367 2012 625 635